Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Cabozantinib and Nivolumab in Advanced HCC
NCT05039736Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by University of Texas MD Anderson Cancer Center. Planned start Feb 2023; status: withdrawn.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05039736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039736.